Josu Aguirre

Josu Aguirre

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2019 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
CBCora Blázquez-Bermejo
Cora Blázquez-Bermejo
LCLidia Carreño-Gago
Lidia Carreño-Gago
DMDavid Molina-Granada
David Molina-Granada
JAJosu Aguirre
Josu Aguirre
JRJavier Ramón
Javier Ramón
YCYolanda Cámara
Yolanda Cámara
Polymerase γ catalytic subunit ( POLG ) gene encodes the enzyme responsible for mitochondrial DNA (mtDNA) synthesis. Mutations affecting POLG are the most prevalent cause of mitochondrial disease because of defective mtDNA replication and lead to a wide spectrum of clinical phenotypes characterized by mtDNA deletions or depletion. Enhancing mitochondrial deoxyribonucleoside triphosphate (dNTP) synthesis effectively rescues mtDNA depletion in different models of defective mtDNA maintenance due to dNTP insufficiency. In this study, we studied mtDNA copy number recovery rates following ethidium bromide‐forced depletion in quiescent fibroblasts from patients harboring mutations in different domains of POLG. Whereas control cells spontaneously recovered initial mtDNA levels, POLG‐deficient cells experienced a more severe depletion and could not repopulate mtDNA. However, activation of deoxyribonucleoside (dN) salvage by supplementation with dNs plus erythro ‐9‐(2‐hydroxy‐3‐nonyl) adenine (inhibitor of deoxyadenosine degradation) led to increased mitochondrial dNTP pools and promoted mtDNA repopulation in all tested POLG‐mutant cells independently of their specific genetic defect. The treatment did not compromise POLG fidelity because no increase in multiple deletions or point mutations was detected. Our study suggests that physiologic dNTP concentration limits the mtDNA replication rate. We thus propose that increasing mitochondrial dNTP availability could be of therapeutic interest for POLG deficiency and other conditions in which mtDNA maintenance is challenged.—Blázquez‐Bermejo, C., Carreño‐Gago, L., Molina‐Granada, D., Aguirre, J., Ramon, J., Torres‐Torronteras, J., Cabrera‐Pérez, R., Martín, M. Á., Domínguez‐González, C., de la Cruz, X., Lombès, A., García‐Arumí, E., Martí, R., Cámara, Y. Increased dNTP pools rescue mtDNA depletion in human POLG‐deficient fibroblasts. FASEB J. 33, 7168–7179 (2019). www.fasebj.org

Verified
Journal Article
Open access
PDF file
DNDàmaris Navío
Dàmaris Navío
MRMireia Rosell
Mireia Rosell
JAJosu Aguirre
Josu Aguirre
XCXavier De La Cruz
Xavier De La Cruz
JFJuan Fernandez-Recio
Juan Fernandez-Recio
One of the known potential effects of disease-causing amino acid substitutions in proteins is to modulate protein-protein interactions (PPIs). To interpret such variants at the molecular level and to obtain useful information for prediction purposes, it is important to determine whether they are located at protein-protein interfaces, which are composed of two main regions, core and rim, with different evolutionary conservation and physicochemical properties. Here we have performed a structural, energetics and computational analysis of interactions between proteins hosting mutations related to diseases detected in newborn screening. Interface residues were classified as core or rim, showing that the core residues contribute the most to the binding free energy of the PPI. Disease-causing variants are more likely to occur at the interface core region rather than at the interface rim (p < 0.0001). In contrast, neutral variants are more often found at the interface rim or at the non-interacting surface rather than at the interface core region. We also found that arginine, tryptophan, and tyrosine are over-represented among mutated residues leading to disease. These results can enhance our understanding of disease at molecular level and thus contribute towards personalized medicine by helping clinicians to provide adequate diagnosis and treatments.

Verified
Journal Article
Open access
PDF file
JAJosu Aguirre
Josu Aguirre
NPNatàlia Padilla
Natàlia Padilla
SÖSelen Özkan
Selen Özkan
CRCasandra Riera
Casandra Riera
LFLídia Feliubadaló
Lídia Feliubadaló
XCXavier De La Cruz
Xavier De La Cruz
Pathogenicity predictors are computational tools that classify genetic variants as benign or pathogenic; this is currently a major challenge in genomic medicine. With more than fifty such predictors available, selecting the most suitable tool for clinical applications like genetic screening, molecular diagnostics, and companion diagnostics has become increasingly challenging. To address this issue, we have developed a cost-based framework that naturally considers the various components of the problem. This framework encodes clinical scenarios using a minimal set of parameters and treats pathogenicity predictors as rejection classifiers, a common practice in clinical applications where low-confidence predictions are routinely rejected. We illustrate our approach in four examples where we compare different numbers of pathogenicity predictors for missense variants. Our results show that no single predictor is optimal for all clinical scenarios and that considering rejection yields a different perspective on classifiers.

2 July 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ÒMÒscar Marín
Òscar Marín
JAJosu Aguirre
Josu Aguirre
XCXavier De La Cruz
Xavier De La Cruz
Compensated pathogenic deviations (CPDs) are sequence variants that are pathogenic in humans but neutral in other species. In recent years, our molecular understanding of CPDs has advanced substantially. For example, it is known that their impact on human proteins is generally milder than that of average pathogenic mutations and that their impact is suppressed in non-human carriers by compensatory mutations. However, prior studies have ignored the evolutionarily relevant relationship between molecular impact and organismal phenotype. Here, we explore this topic using CPDs from FVIII and FIX and data concerning carriers’ hemophilia severity. We find that, regardless of their molecular impact, these mutations can be associated with either mild or severe disease phenotypes. Only a weak relationship is found between protein stability changes and severity. We also characterize the population variability of hemostasis proteins, which constitute the genetic background of FVIII and FIX, using data from the 1000 Genome project. We observe that genetic background can vary substantially between individuals in terms of both the amount and nature of genetic variants. Finally, we discuss how these results highlight the need to include new terms in present models of protein evolution to explain the origin of CPDs.

19 February 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
JAJosu Aguirre
Josu Aguirre
NPNatàlia Padilla
Natàlia Padilla
SOSelen Ozkan
Selen Ozkan
CRCasandra Riera
Casandra Riera
LFLídia Feliubadaló
Lídia Feliubadaló
XCXavier De La Cruz
Xavier De La Cruz
Motivation Our inability to solve the Variant Interpretation Problem (VIP) has become a bottleneck in the biomedical/clinical application of Next-Generation Sequencing. This situation has favored the development and use of in silico tools for the VIP. However, choosing the optimal tool for our purposes is difficult because of a fact usually ignored: the high variability of clinical context/scenarios across and within countries, and over time. Results We have developed a computational procedure, based on the use of cost models, that allows the simultaneous comparison of an arbitrary number of tools across all possible clinical scenarios. We apply our approach to a set of pathogenicity predictors for missense variants, showing how differences in clinical context translate to differences in tool ranking. Availability The source code is available at: https://github.com/ClinicalTranslationalBioinformatics/clinical_space_partition